Renin-Angiotensin System and Other Markers in Strawberry Birthmarks in infants and young children with growing problematic haemangiomas

Not Applicable

Withdrawn

• Conditions: Infantile Haemangioma; Skin - Dermatological conditions

• Registration Number: ACTRN12612001227886
• Lead Sponsor: Hutt Valley DHB

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2012-11-20
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Withdrawn
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

1. Infants and young children aged 2 to 18 months with growing problematic haemangiomas undergoing Propranolol treatment or surgery, whose caregivers have already decided on the proposed treatment and have given written consent.
2. Non-haemangioma children aged 3 – 18 months undergoing elective surgery for whose caregiver have given written consent.

Exclusion Criteria

1. Caregivers who would not consent for the child to participate in this study.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary outcome we are looking for is to compare the serial serum ACE, Angiotensin II, and Renin Levels in patients undergoing propranolol treatment for haemangioma, with those undergoing captopril and surgical treatment. These will be measured by venous blood analysis.[Serial measurements of RAS components at four time points. These include pre treatment, one month following start of treatment, 6 months following start of treatment and 12 months following start of treatment.]

Secondary Outcome Measures

Name	Time	Method
The secondary outcome we are looking for is to compare the serial serum alpha-feto protein (AFP) levels in patients undergoing propranolol treatment for haemangioma, with those undergoing captopril and surgical treatment. This will be measured by venous blood analysis. If AFP levels are outside of normal range, an abdominal ultrasound scan will be done to exclude liver abnormailities.[Serial measurements of AFP at four time points. These include pre treatment, one month following start of treatment, 6 months following start of treatment and 12 months following start of treatment.]